0000000000210366

AUTHOR

Leanne Dyal

showing 2 related works from this author

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.

2021

Abstract Aims Peripheral artery disease (PAD) patients suffer a high risk of major cardiovascular (CV) events, with athero-thrombo-embolism as the underlying pathophysiologic mechanism. Recently, two large randomized clinical trials evaluated the efficacy and safety of low-dose rivaroxaban twice daily plus aspirin in stable PAD outpatients and those immediately after peripheral revascularization. We sought to determine if the effects of low-dose rivaroxaban and aspirin compared to aspirin alone are consistent across this broad spectrum of PAD patients. Methods and results We conducted a random-effects meta-analysis of the COMPASS and VOYAGER randomized trials among 11 560 PAD patients (4996…

medicine.medical_specialtyAcute limb ischaemiaEpidemiologymedicine.medical_treatmentHemorrhageRevascularizationlaw.inventionBrain IschemiaPeripheral Arterial DiseaseRandomized controlled trialFibrinolytic AgentsRivaroxabanlawIschemiaInternal medicineMedicineHumansMyocardial infarctionAspirinRivaroxabanAspirinbusiness.industryHazard ratiomedicine.diseaseStrokeAmputationCardiologyDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsEuropean journal of preventive cardiology
researchProduct

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with an…

2020

Digital

medicine.medical_specialtyProportional hazards modelbusiness.industryHazard ratioType 2 diabetes030204 cardiovascular system & hematologyCardiovascular diseasemedicine.diseasePlaceboMetforminMetformin03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineGLP-1-based therapymedicineDulaglutide030212 general & internal medicinePrediabetesMortalityMorbidityCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct